A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 10, 2008, Pages 1006-1011

  Kumar, Yogesh ^a   Pinedo, Inigo R ^a   Tapuria, Niteen ^a   Zabron, Abigail ^a   Davidson, Brian R ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CA19 9; Carcinoembryonic antigen; Colorectal liver metastasis; Tumour M2 pyruvate kinase

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PYRUVATE KINASE; TUMOR M2 PYRUVATE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIVER METASTASIS; LIVER RESECTION; MALE; MINIMAL RESIDUAL DISEASE; NORMAL VALUE; PRIORITY JOURNAL; TISSUE DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CHEMILUMINESCENT MEASUREMENTS; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PYRUVATE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 53549117129     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f857a7     Document Type: Article

References (37)

1. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg 1999; 86:158-169.
2. Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH. Hepatic resection for metastases from colorectal carcinoma: a survival analysis. Eur J Cancer 1995; 31A:41-46.
3. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38:619-626.
4. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002; 324:81 3.
5. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 1997; 17:3153-3156.
6. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 1992; 3:91-115.
7. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15:300-308.
8. Mazurek S, Michel A, Eigenbrodt E. Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates. J Biol Chem 1997; 272:4941-4952.
9. McKeehan WL Glycolysis, glutaminolysis and cell proliferation. Cell Biol Int Rep 1982; 6:635-650.
10. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 1999; 19:2599-2601.
11. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004; 49:1149-1155.
12. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22:311-318.
13. Yilmaz S, Ozan S, Ozercan IH. Comparison of pyruvate kinase variants from breast tumor and normal breast. Arch Med Res 2003; 34:315-324.
14. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007; 19:265-276.
15. Zhang B, Chen JY, Chen DD, Wang GB, Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 2004; 10:1643-1646.
16. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91:980-984.
17. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Anticancer Res 2003; 23:855-857.
18. Eigenbrodt E, Mazurek S, Friis R. Double role for pyruvate kinase type M2 in the regulation of phosphometabolite pools. In: Bannasch P, Kanduc D, Papa S, Tager J, editors. Cell growth and oncogenesis. Basel, Switzerland: Birkhauser Verlag; 1998. pp. 15-30.
19. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999; 19:2583-2590.
20. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000; 20:4965-4968.
21. Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF, Davidson BR. Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 2004; 91:1361-1369.
22. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, Starzl TE. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994; 116:703-710.
23. Bhattacharjya S, Aggarwal R, Davidson BR. Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen - a prospective study. Br J Cancer 2006; 95:21-26.
24. Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003; 23:5089-5093.
25. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 2000; 20:4961-4964.
26. Siriwardana P, King NK, France MW, Siriwardena AK. Prospective evaluation of the diagnostic accuracy of plasma tumour M2-pyruvate kinase (TuM2-PK) and serum carbohydrate antigen (CA19-9) in periampullary cancer. Gastroenterology 2005; 128:S2 A472-S2 A473.
27. Lewis JC, Keep PA. Relationship of serum CEA levels to tumour size and CEA content in nude mice bearing colonic-tumour xenografts. Br J Cancer 1981;44:381-387.
28. Staab HJ, Anderer FA. Growth of human colonic adenocarcinoma and development of serum CEA in in athymic mice. I: strict correlation of tumour size and mass with serum CEA concentration during logarithmic growth. Br J Cancer 1982; 46:841-847.
29. Staab HJ, Anderer FA. Circulating carcinoembryonic antigen (CEA), a growth parameter in malignant disease. Cancer Detect Prev 1983; 6:33-39.
30. Ishizuka D, Shirai Y, Sakai Y, Hatakeyama K. Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels. Int J Colorectal Dis 2001 ; 16:32-37.
31. Quayle JB. Ability of CEA blood levels to reflect tumour burden: a study in a human xenograft model. Br J Cancer 1982; 46:220-227.
32. Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 2000; 24:531-535.
33. Dixit A, Baquer NZ, Rao AR. Inhibition of key enzymes of carbohydrate metabolism in regenerating mouse liver by ascorbic acid. Biochem Int 1992; 26:143-151.
34. Chen SH. Further study on the value of M2-type pyruvate kinase in the diagnosis of primary hepatocarcinoma. Zhonghua Zhong Liu Za Zhi 1993; 15:268-271.
35. Chatzipanagiotou S, Nath A, Vogt B, Jungermann K. Alteration in the capacities as well as in the zonal and cellular distributions of pyruvate kinase L and M2 in regenerating rat liver. Biol Chem Hoppe Seyler 1985; 366:271-280.
36. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20:5077-5082.
37. Schneider J, Neu K, Velcovsky HG, Morr H, Eigenbrodt E. Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett 2003; 193:91-98.